Papers
5
Total Citations
110
H-Index
5
About
Kevin Hakimi is a urologic oncologist whose research focuses on advancing the surgical management of upper tract urothelial carcinoma (UTUC) and rare bladder malignancies. As a key contributor to the international ROBUUST collaborative group, Hakimi has led landmark multicenter studies comparing robotic versus laparoscopic nephroureterectomy, demonstrating that robotic approaches achieve superior “tetrafecta” outcomes—a composite of oncologic control, complication avoidance, and functional preservation. His work has been instrumental in defining the role of lymph node dissection during nephroureterectomy, showing that meticulous nodal staging improves survival prognostication in UTUC patients. With over 110 citations across his most influential papers, Hakimi has also investigated health disparities in UTUC survival by race and the utility of neoadjuvant chemotherapy for node-positive disease, providing real-world evidence from the ROBUUST 2.0 registry. Beyond UTUC, he has pioneered single-port robotic techniques for urachal adenocarcinoma, showcasing innovative minimally invasive approaches. Hakimi’s contributions have shaped contemporary guidelines for UTUC surgery and established benchmarks for robotic outcomes in complex urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5Single-Port Robot assisted partial cystectomy for urachal adenocarcinoma5 citations · 2024